Rizatriptan Benzoate Tablet
Product Images NDC 71335-1912

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 71335-1912). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (Lbl713351912)

Packaging label for Rizatriptan Benzoate 10 mg tablet in blister pack, labeled for oral use. The label includes storage instructions to keep at 20°-25°C (68°-77°F) and notes to keep drugs out of reach of children. The product is packed by Bryant Ranch Prepack located in Burbank, CA, and the package size is 10 tablets. The label also references Maxalt 10 mg tablet for comparison and displays the NDC 71335-1912.*

FDA Label Image

Figure 1: Estimated Probability Of Achieving An Initial Headache Response By 2 Hours In Pooled Studies 1, 2, 3, And 4†† (Rizatriptan Fig1)

A line graph showing the estimated probability of achieving an initial headache response by 2 hours in pooled placebo-controlled outpatient studies. The X-axis represents hours post-dose (0 to 2), and the Y-axis shows the estimated probability of response (0% to 100%). Three lines compare placebo, Rizatriptan Benzoate 5 mg, and Rizatriptan Benzoate 10 mg, illustrating higher response probabilities with Rizatriptan Benzoate doses over time.*

FDA Label Image

Figure 2: Estimated Probability Of Patients Taking A Second Dose Of Rizatriptan Benzoate Tablets Or Other Medication For Migraines Over The 24 Hours Following The Initial Dose Of Study Treatment In Pooled Studies 1, 2, 3, And 4††† (Rizatriptan Fig2)

Kaplan-Meier plot showing the estimated probability of patients taking a second dose of Rizatriptan Benzoate tablets or other migraine medication over 24 hours post initial dose in pooled clinical studies. The graph compares placebo, Rizatriptan Benzoate 5 mg, and 10 mg treatment groups.*

FDA Label Image

Figure 5: Observed Percentage Of Patients Reporting No Headache Pain By 2 Hours Post-dose In Study 7 (Rizatriptan Fig3)

A line graph showing the observed percentage of patients reporting no headache pain by 2 hours after dosing in Study 7. The x-axis represents hours post dose (0.5 to 2.0), and the y-axis represents percentage of patients (0% to 100%). Two lines compare Rizatriptan Benzoate orally disintegrating tablets and placebo, with Rizatriptan showing a higher percentage over time.*

FDA Label Image

Chemical Structure (Rizatriptan Str)

Chemical structure of Rizatriptan Benzoate, showing its molecular framework including indole and benzoate components.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.